REVIEW Flutamide is an oral, non-steroidal antiandrogen drug primarily used to treat prostate cancer. It competes with both endogenous and exogenous testosterone and its powerful metabolite, dihydrotestosterone (DHT) for binding to androgen receptors in the prostate gland. By doing so, it prevents them from stimulating the prostate cancer cells to grow. Flutamide may also be used to treat excess androgen levels in women - especially those with PolyCystic Ovarian Syndrome (PCOS). In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen.
Sogani PC, Whitmore WF Jr. Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma. Cancer Treat Res. 1988;39:131-45.
Newling DW.The use of flutamide as monotherapy in the treatment of advanced prostate cancer. Prog Clin Biol Res. 1989;303:117-21.
Brogden RN, Clissold SP. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs. 1989 Aug;38(2):185-203.
Goldspiel BR, Kohler DR. Flutamide: an antiandrogen for advanced prostate cancer. DICP. 1990 Jun;24(6):616-23+Brogden RN, Chrisp P.Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer. Drugs Aging. 1991 Mar;1(2):104-15.